Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) EBT Margin (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of EBT Margin data on record, last reported at 244.66% in Q4 2025.

  • For Q4 2025, EBT Margin rose 35798.0% year-over-year to 244.66%; the TTM value through Dec 2025 reached 86.6%, up 10902.0%, while the annual FY2025 figure was 471.61%, 27599.0% down from the prior year.
  • EBT Margin reached 244.66% in Q4 2025 per LCTX's latest filing, up from 92.91% in the prior quarter.
  • Across five years, EBT Margin topped out at 244.66% in Q4 2025 and bottomed at 1382.81% in Q2 2021.
  • Average EBT Margin over 5 years is 336.63%, with a median of 260.14% recorded in 2023.
  • Peak YoY movement for EBT Margin: skyrocketed 126936bps in 2021, then crashed -38852bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 389.69% in 2021, then plummeted by -41bps to 550.97% in 2022, then skyrocketed by 58bps to 230.51% in 2023, then skyrocketed by 51bps to 113.32% in 2024, then skyrocketed by 316bps to 244.66% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 244.66% in Q4 2025, 92.91% in Q3 2025, and 698.95% in Q2 2025.